H Lundbeck A/S (OTCPK:HLUYY) (LUN.CO) remains in a "hurry up and wait" gray area. Key drugs like Brintellix and Abilify Maintena are only just getting started and investors are on tenterhooks waiting for Phase III data on key pipeline candidates like brexpiprazole and desmoteplase. While the shares still look undervalued today, further progression in the Brintellix launch and key pipeline updates will likely lead to significant revisions in estimated value before 2014 is over.
Mixed News For Q1
Lundbeck's first quarter results looked a little stronger than they really were, as the company didn't outperform where analysts and investors most wanted to see outperformance.
Revenue declined 22% as reported, coming in just below expectations. Old drugs like Cipralex...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|